A Study of COVID-19 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a phase I, randomized, observer-blinded, placebo-controlled and dose-escalation
clinical trial to evaluate the safety, tolerability, immunogenicity and immune persistence of
SYS6006 (COVID-19 mRNA Vaccine) in 18-59 year old healthy population.